BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Regulatory & Policy
FDA Advisory Panel Votes to Recommend BPC-157, KPV, TB-500 and MOTS-c for Compounding — Defying Its Own Scientists
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on 23 July 2026 to recommend four peptides — BPC-157, KPV, TB-500, and MOTS-c — for inclusion on the 503A Bulk Drug Substances List, against the agency's own staff recommendations. Day 2 votes on Emideltide, Semax, and Epitalon conclude today. The panel's recommendations are non-binding, and formal rulemaking could take twelve months or more.
25 Jul 2026
Regulatory & Policy
FDA Scientists Advise Against Peptide Compounding Access as PCAC Panel Composition Draws Scrutiny — What It Means for the July 23-24 Review
With three weeks to go before the FDA's Pharmacy Compounding Advisory Committee meets to review seven peptides including Semax, Emideltide, BPC-157, and MOTS-c, FDA career scientists have publicly recommended against easing compounding restrictions — placing agency staff in direct tension with HHS Secretary Kennedy's stated position. Simultaneously, scrutiny of the panel's composition has intensified after it emerged that several members have financial ties to the peptide industry.
02 Jul 2026
Regulatory & Policy
FDA's 503B Bulks List Proposal: What Today's Comment Deadline Means for GLP-1 Peptide Compounding
Today, 29 June 2026, marks the close of the FDA's public comment period on its proposal to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility Bulks List. If finalised, the rule would permanently bar large-scale bulk compounding of these three GLP-1 agents — regardless of future market conditions. UK research procurement teams and supply-chain professionals should understand what the 503B framework is, how the proposal sits alongside the parallel PCAC…
29 Jun 2026
Regulatory & Policy
FDA's Proposed Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide from the 503B Bulks List: What the 29 June Comment Deadline Means for Research Procurement
The FDA has proposed permanently barring 503B outsourcing facilities from bulk-compounding semaglutide, tirzepatide and liraglutide, finding no clinical need for their inclusion on the 503B Bulks List. With the public comment window closing on 29–30 June 2026, research procurement professionals should understand what the rule would foreclose, which legal pathways remain, and how the diverging US regulatory posture contrasts with the UK framework.
18 Jun 2026
Regulatory & Policy
Semax and Epitalon at the July 2026 PCAC: What the Day-Two Agenda and Dual June Deadlines Mean for Research Procurement
Two high-profile peptides — Semax and Epitalon — are scheduled for FDA Pharmacy Compounding Advisory Committee review on 24 July 2026. With oral-comment requests due 30 June and a parallel 503B GLP-1 exclusion deadline on 29 June, UK procurement teams face a concentrated window of US regulatory activity that will shape licit supply chains for both compounds.
17 Jun 2026
Regulatory & Policy
MHRA Approves Oral Semaglutide for Weight Management: What the UK's First GLP-1 Pill Means for Research Procurement
The MHRA approved oral semaglutide 25 mg (Wegovy pill) for weight management on 11 June 2026, making it the first oral GLP-1 receptor agonist licensed for obesity in the UK. Coming within weeks of the FDA's approval of orforglipron (Foundayo) and new Phase 3 data for retatrutide, the decision reshapes the incretin research landscape and has direct implications for UK labs procuring GLP-1 reference compounds.
15 Jun 2026
Regulatory & Policy
FDA Proposes Permanent 503B Exclusion of GLP-1 Peptides: What the 30 June Deadline Means for Research and Procurement
The FDA's 30 April 2026 proposal to formally bar semaglutide, tirzepatide, and liraglutide from the 503B Bulks List closes the last major regulatory pathway for large-scale GLP-1 compounding. With the public comment window closing on 29–30 June 2026, UK and US research labs need to understand what this finalisation would mean for procurement, quality assurance, and parallel July 2026 developments on other peptides.
06 Jun 2026
Regulatory & Policy
The PCAC July 2026 Hearing: What the Four Day-One Peptides — BPC-157, TB-500, KPV, and MOTS-c — Need to Prove Before the Review
On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee will evaluate BPC-157, TB-500, KPV, and MOTS-c for potential inclusion on the Section 503A Bulk Drug Substances List. With the oral-testimony registration deadline on 30 June and the cut-off for comments reaching the committee on 9 July, procurement teams have weeks — not months — to understand what is at stake.
01 Jun 2026
Regulatory & Policy
FDA Moves to Close 503B Compounding Pathway for GLP-1 Peptides — What the April Proposal Means Before the June Comment Deadline
On 30 April 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List, citing no clinical need for outsourcing facilities to compound these agents. The public comment window closes 29 June 2026 — and the implications extend well beyond US compounders to research procurement teams tracking GLP-1 supply integrity globally.
29 May 2026
Regulatory & Policy
Twelve peptides off Category 2: what April's reclassification means before the July PCAC review
The FDA's removal of twelve peptide bulk drug substances from Category 2 in late April was procedural, not permissive. It clears a path for the Pharmacy Compounding Advisory Committee to review them at its 23-24 July meeting, but until then the affected peptides — including BPC-157, Epitalon, KPV and TB-500 — sit in a regulatory grey area that procurement teams need to understand.
18 May 2026
Regulatory & Policy
FDA Proposes to Close Large-Scale GLP-1 Compounding for Good, Targeting the 503B Outsourcing Pathway
The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these GLP-1 drugs from bulk substances. The move would close the last remaining large-scale compounding pathway, with implications for API supply, research procurement, and the broader peptide market.
09 May 2026
Regulatory & Policy
FDA Tightens GLP-1 Compounding Rules While Scheduling First Formal Review of BPC-157, TB-500 and Five Other Peptides
The FDA issued a proposal on 30 April 2026 to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list, citing no clinical need. Separately, the agency has confirmed a two-day Pharmacy Compounding Advisory Committee meeting on 23–24 July 2026 to evaluate seven peptides — including BPC-157, TB-500 and Semax — for potential inclusion on the 503A Bulks List, the first formal step toward regulated compounding access since twelve substances were removed from…
07 May 2026